413 related articles for article (PubMed ID: 24965547)
1. The future of drug discovery: enabling technologies for enhancing lead characterization and profiling therapeutic potential.
Janero DR
Expert Opin Drug Discov; 2014 Aug; 9(8):847-58. PubMed ID: 24965547
[TBL] [Abstract][Full Text] [Related]
2. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
3. Mesopore-assisted profiling strategies in clinical proteomics for drug/target discovery.
Savino R; Terracciano R
Drug Discov Today; 2012 Feb; 17(3-4):143-52. PubMed ID: 22016086
[TBL] [Abstract][Full Text] [Related]
4. Improving drug candidates by design: a focus on physicochemical properties as a means of improving compound disposition and safety.
Meanwell NA
Chem Res Toxicol; 2011 Sep; 24(9):1420-56. PubMed ID: 21790149
[TBL] [Abstract][Full Text] [Related]
5. The impact of assay technology as applied to safety assessment in reducing compound attrition in drug discovery.
Thomas CE; Will Y
Expert Opin Drug Discov; 2012 Feb; 7(2):109-22. PubMed ID: 22468913
[TBL] [Abstract][Full Text] [Related]
6. Chemical proteomics and its impact on the drug discovery process.
Miao Q; Zhang CC; Kast J
Expert Rev Proteomics; 2012 Jun; 9(3):281-91. PubMed ID: 22809207
[TBL] [Abstract][Full Text] [Related]
7. Identification and characterization of molecular targets of natural products by mass spectrometry.
Cheng KW; Wong CC; Wang M; He QY; Chen F
Mass Spectrom Rev; 2010; 29(1):126-55. PubMed ID: 19319922
[TBL] [Abstract][Full Text] [Related]
8. Predictive in silico off-target profiling in drug discovery.
Schmidt F; Matter H; Hessler G; Czich A
Future Med Chem; 2014 Mar; 6(3):295-317. PubMed ID: 24575966
[TBL] [Abstract][Full Text] [Related]
9. Chemoproteomic approaches to drug target identification and drug profiling.
Bantscheff M; Drewes G
Bioorg Med Chem; 2012 Mar; 20(6):1973-8. PubMed ID: 22130419
[TBL] [Abstract][Full Text] [Related]
10. Native MS: an 'ESI' way to support structure- and fragment-based drug discovery.
Vivat Hannah V; Atmanene C; Zeyer D; Van Dorsselaer A; Sanglier-Cianférani S
Future Med Chem; 2010 Jan; 2(1):35-50. PubMed ID: 21426045
[TBL] [Abstract][Full Text] [Related]
11. Chemistry-based functional proteomics for drug target deconvolution.
Wang K; Yang T; Wu Q; Zhao X; Nice EC; Huang C
Expert Rev Proteomics; 2012 Jun; 9(3):293-310. PubMed ID: 22809208
[TBL] [Abstract][Full Text] [Related]
12. Structural proteomics in drug discovery.
Tari LW; Rosenberg M; Schryvers AB
Expert Rev Proteomics; 2005 Aug; 2(4):511-9. PubMed ID: 16097885
[TBL] [Abstract][Full Text] [Related]
13. Towards quantitative biology: integration of biological information to elucidate disease pathways and to guide drug discovery.
Fischer HP
Biotechnol Annu Rev; 2005; 11():1-68. PubMed ID: 16216773
[TBL] [Abstract][Full Text] [Related]
14. Proteomics and systems biology: application in drug discovery and development.
Chakravarti B; Mallik B; Chakravarti DN
Methods Mol Biol; 2010; 662():3-28. PubMed ID: 20824464
[TBL] [Abstract][Full Text] [Related]
15. [Biomarkers: "Found in translation"].
Lockhart BP; Walther B
Med Sci (Paris); 2009 Apr; 25(4):423-30. PubMed ID: 19409197
[TBL] [Abstract][Full Text] [Related]
16. From targets to leads: the importance of advanced data analysis for decision support in drug discovery.
Fischer HP; Heyse S
Curr Opin Drug Discov Devel; 2005 May; 8(3):334-46. PubMed ID: 15892249
[TBL] [Abstract][Full Text] [Related]
17. Network approaches to drug discovery.
Chandra N; Padiadpu J
Expert Opin Drug Discov; 2013 Jan; 8(1):7-20. PubMed ID: 23140510
[TBL] [Abstract][Full Text] [Related]
18. Proteomics technology and therapeutics.
Hong ML; Jiang N; Gopinath S; Chew FT
Clin Exp Pharmacol Physiol; 2006; 33(5-6):563-8. PubMed ID: 16700895
[TBL] [Abstract][Full Text] [Related]
19. Rational approaches to natural-product-based drug design.
Haustedt LO; Mang C; Siems K; Schiewe H
Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
[TBL] [Abstract][Full Text] [Related]
20. Alternative strategies in drug development: clinical pharmacological aspects.
Kuhlmann J
Int J Clin Pharmacol Ther; 1999 Dec; 37(12):575-83. PubMed ID: 10599949
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
